乳腺癌治疗中右心室心肌FDG摄取与心脏毒性的关联
BACKGROUND: The aim of this study was to investigate changes in myocardial uptake evaluated by oncologic 18F-fluorodeoxyglucose (FDG) PET/CT scans and to determine the relationship between myocardial FDG uptake and cancer therapy-induced cardiotoxicity in breast cancer patients w…
要点
- 乳腺癌蒽环类或曲妥珠单抗治疗后,右室壁FDG摄取存在与心脏毒性相关。
- 右室壁SUV>1.8及ΔSUV>0.4与心脏毒性显著相关,校正年龄、放疗和治疗后仍显著。
- 肿瘤FDG PET/CT在评估肿瘤疗效的同时可提供治疗相关心脏毒性信息。
核心结论
- 治疗后PET/CT上右室壁FDG摄取存在及右室壁SUV升高与乳腺癌患者蒽环类或曲妥珠单抗治疗相关心脏毒性相关。
- 肿瘤FDG PET/CT除评估肿瘤疗效外,还可提供癌症治疗所致心脏毒性的信息。
研究设计与样本
- 回顾性研究,纳入121例连续接受肿瘤FDG PET/CT和超声心动图(基线与治疗后)的乳腺癌患者,治疗为蒽环类或曲妥珠单抗。
- 采用视觉分析评估左室壁分级、左室壁摄取模式和右室壁摄取存在,定量分析测量左室和右室壁平均SUV及基线与治疗间SUV变化(ΔSUV)。
- 采用多因素logistic回归分析评估PET参数与心脏毒性的关联。
主要发现
- 心脏毒性组在蒽环类或曲妥珠单抗治疗后倾向于更弥漫的左室摄取、更高的SUV及更高的右室壁ΔSUV。
- logistic回归分析显示,在校正年龄、放疗和治疗后,右室壁摄取存在、右室壁SUV(>1.8)和右室壁ΔSUV(>0.4)与心脏毒性显著相关。
关键数值与推荐
- 右室壁摄取存在与心脏毒性显著相关(多因素logistic回归,校正年龄、放疗和治疗)。
- 右室壁SUV>1.8与心脏毒性显著相关(多因素logistic回归,校正年龄、放疗和治疗)。
- 右室壁ΔSUV>0.4与心脏毒性显著相关(多因素logistic回归,校正年龄、放疗和治疗)。
临床怎么用
- 对接受蒽环类或曲妥珠单抗治疗的乳腺癌患者,阅肿瘤FDG PET/CT时可关注右室壁FDG摄取存在及右室壁SUV和ΔSUV变化。
- 右室壁摄取存在、右室壁SUV>1.8或ΔSUV>0.4时,可提示临床关注治疗相关心脏毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to investigate changes in myocardial uptake evaluated by oncologic 18F-fluorodeoxyglucose (FDG) PET/CT scans and to determine the relationship between myocardial FDG uptake and cancer therapy-induced cardiotoxicity in breast cancer patients who underwent anthracycline or trastuzumab. METHODS: We reviewed 121 consecutive patients who underwent oncologic FDG PET/CT and echocardiography at baseline and post-therapy with anthracyclines or trastuzumab for breast cancer. Grade in LV wall, uptake pattern in LV wall, and the presence of RV wall uptake were assessed by visual analysis, and the mean SUV in the LV and RV walls and the change of SUV (ΔSUV) between baseline and post-therapy PET/CT were measured by quantitative analysis. Multiple logistic regression analyses were performed to evaluate the association between PET parameters and cardiotoxicity. RESULTS: Fifteen patients (12%) showed cardiotoxicity after therapy. The cardiotoxic group tended to show more diffuse LV uptake, higher SUV, and ΔSUV of RV wall than the non-cardiotoxic group following therapy with anthracyclines or trastuzumab. Logistic regression analysis showed that the presence of RV wall uptake, SUV of RV wall (> 1.8), and ΔSUV of RV wall (> 0.4) were significantly associated with cardiotoxicity after controlling for age, radiotherapy, and treatment. CONCLUSIONS: The presence of RV wall uptake and the increase of SUV of RV wall on post-therapy PET/CT were associated with cardiotoxicity in breast cancer patients who underwent anthracycline or trastuzumab. Oncologic FDG PET/CT scans can provide information regarding cancer therapy-induced cardiotoxicity as well as tumor response.
引用
- Kim J, Cho SG, Kang SR, et al. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2019. PMID: 30719656. doi:10.1007/s12350-019-01617-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。